## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.6% below STRENGTH zone (3.0-6.0%); PEG 4.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($645.53)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Osaic Holdings Inc. Has $6.31 Million Stock Position in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251223T103915 | Bullish | Relevance: 100%
- Osaic Holdings Inc. increased its stake in IDEXX Laboratories (NASDAQ: IDXX) by 15.9% to 12,458 shares, valued at $6.31 million. Concurrently, IDEXX EVP Nimrata Hunt sold 9,425 shares for $6.63 million, reducing her holdings by 30.83%. Analysts maintain a "Moderate Buy" rating for IDEXX, with an average price target of $763.50, following strong earnings reporting $3.22 EPS and $1.11 billion in revenue, along with a projected FY2025 EPS of $12.81-$13.01.

**2. Riverbridge Partners LLC Reduces Holdings in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251222T125432 | Neutral | Relevance: 100%
- Riverbridge Partners LLC has reduced its stake in IDEXX Laboratories, Inc. ($IDXX) by 3.9% in Q3, selling 3,897 shares and now holding 95,433 shares valued at approximately $60.97 million. Concurrently, IDEXX EVP Nimrata Hunt sold 9,425 shares for about $6.63 million, decreasing her position by 30.83%. Despite these sales, analysts generally maintain a "Moderate Buy" rating with a consensus target price of $763.50, following strong Q3 earnings and positive FY2025 guidance.

**3. IDEXX Laboratories, Inc. $IDXX Shares Sold by Seilern Investment Management Ltd**
- Source: MarketBeat | 20251222T110838 | Bullish | Relevance: 100%
- Seilern Investment Management Ltd significantly reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 33.4% in the third quarter, selling 70,900 shares, though it remains a top-five holding in their portfolio. Concurrently, IDEXX EVP Nimrata Hunt sold 9,425 shares for approximately $6.63 million, decreasing her ownership by 30.83%. Despite these sales, analysts generally maintain a "Moderate Buy" rating for IDEXX, with a consensus price target of $763.50, following the company's strong Q3 earnings and positive FY2025 guidance.

**4. 3,727 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by USA Financial Formulas**
- Source: MarketBeat | 20251221T131203 | Bullish | Relevance: 100%
- USA Financial Formulas recently acquired 3,727 shares of IDEXX Laboratories, valued at approximately $2.38 million, making it their 22nd largest holding. This comes as IDEXX Laboratories reported strong Q3 earnings, beating analyst estimates for EPS and revenue, and issued positive FY2025 EPS guidance. Despite an EVP's significant share sale, institutional investors maintain a substantial stake in the company, which also holds a "Moderate Buy" consensus analyst rating.

**5. Westwind Capital Decreases Stake in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251223T142048 | Neutral | Relevance: 98%
- Westwind Capital reduced its stake in IDEXX Laboratories by 31.9% in the third quarter, selling 14,604 shares and holding 31,141 shares valued at $19.9 million. This adjustment makes IDEXX its 9th largest holding, representing 4.1% of its portfolio. Meanwhile, IDEXX beat Q3 estimates, increased revenue by 13.3% year-over-year, and set positive FY2025 guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-5.2% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.1x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.12 signals overvaluation risk, limited margin of safety. Forward P/E 47.3x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $54.6B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.12 |
| Forward P/E | 47.3 |
| Current P/E | 52.9 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.7% to -3.6% (-5.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.6pp (needs >3.0% for momentum thesis). Underperforming sector by 3.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-4.37), momentum weakening. RSI neutral at 41. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.58% (CS: 13) | Weak |
| RSI_14 | 40.7 | Neutral |
| MACD Histogram | -4.37 | Bearish |
| vs SMA20 | 0.955x | Below |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 1.187x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $682.31
- **Stop Loss:** $645.53 (5.4% risk)
- **Target:** $719.09 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 32
- **Position Value:** $21,833.92
- **Portfolio %:** 21.83%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*